Orexigen Therapeutics Inc. (OREX)

0.2229 0 (0%)

IEX Real-Time Price

April 3, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 0.2229

Price Open 0.2449

Volume: 3.73M

Avg Volume: 2.12M

Market Cap: 4.21M

P/E Ratio -

52 Wk Range 0.1708-3.805



OREX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-03-15
18.53M
741,785
0.40
4.00%

2018-02-28
18.53M
1.14M
1.18
6.13%

2018-02-15
18.53M
1.03M
3.16
5.53%

2018-01-31
18.39M
877,084
3.39
4.77%




OREX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-04-03
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-03-27
Q4 2017
N/A
-2.06 (1)
0.00
0.00

2017-11-13
Q3 2017
AMC
-2.13 (1)
-1.35
0.78

2017-08-08
Q2 2017
AMC
-2.40 (1)
-1.82
0.58

News

Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed (2018-03-24 01:55 SeekingAlpha)

Novo Nordisk (NVO) may soon be entering the weight loss market with its next-generation GLP-1 receptor agonist semaglutide. Results published this week , March 19, for a Phase II trial conducted on non-diabetics showed that the drug, already used to successfully treat diabetes by, among other…

 

Orexigen Files For Bankruptcy - Investors Need To Get Savvy (2018-03-19 13:58 SeekingAlpha)

Orexigen ( OREX ) investors got a bit of a shocker this week when the company announced that it was filing for Chapter 11 bankruptcy . The news took the stock down from about $1.40 per share to a paltry $0.25 cents per share that it currently trades at. Investors are now left scurrying for a …

 

Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA (2018-03-13 07:30 SeekingAlpha)

Analysis of top Seeking Alpha coverage: Coherus Biosciences Today we will discuss Coherus Biosciences (CHRS), which surged last Friday after the company announced that it is set to resubmit its application for Neulasta biosimilar. The company also noted that it expects an approval for the…

 

Midday Gainers / Losers (3/12/2018) (2018-03-12 12:45 SeekingAlpha)

Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more …

 

Premarket Losers as of 9:05 am (3/12/2018) (2018-03-12 09:11 SeekingAlpha)

ANTH -84% on terminating development of Sollpura after failed late-stage study. More news on: Anthera Pharmaceuticals, Inc., Orexigen Therapeutics, Inc., Savara Inc., Stocks on the move, , Read more …

 


Statistics

Shares Outstanding: 18.89M

Top 15 Institution Percent: 42.10

Price To Sales: 0.15

Price To Book: 0.90

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -53.76

Return On Equity: -2625.21

Profit Margin: N/A

Price History

Beta: 2.40

50-day Moving Avg: 0.82

200-day Moving Avg: 1.74

YTD Change: -82.31

5-day Change: 17.38

1-month Change: -82.45

3-month Change: -81.43

6-month Change: -89.28

1-year Change: -91.92

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Orexigen Therapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Drug Manufacturers

Sector: Healthcare

Website: http://www.orexigen.com

Orexigen Therapeutics Inc is an emerging pharmaceutical company. The company is developing neuroscience drugs that will ultimately address obesity and weight related medical issues.